Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript

Core Viewpoint - Gossamer Bio Inc. announced the top line results from the PROSERA Phase III study of seralutinib for pulmonary arterial hypertension, indicating significant progress in their clinical development pipeline [2]. Group 1: Study Results - The PROSERA study is a Phase III clinical trial focused on seralutinib, which targets pulmonary arterial hypertension [2]. - The results from the study were released in a press release available on the company's Investors section of their website [2]. Group 2: Company Leadership - The call featured Gossamer executives including COO & CFO Bryan Giraudo, along with other key team members such as Faheem Hasnain, Dr. Richard Aranda, Bob Smith, Dr. Rob Roscigno, and Caryn Peterson [2].